Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Immunocore Holdings PLC Sponsored ADR IMCR

Healthcare  —  Biotechnology
30.72 (0.57) (1.82%) as of 25 Sep
Market cap
$1.6B
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Immunocore Holdings PLC Sponsored ADR (IMCR) Business Profile

Updated before January 2025

Company Overview

Immunocore Holdings PLC Sponsored ADR (IMCR) is a pioneering biotechnology company specializing in the development of innovative therapies for the treatment of cancer, infectious diseases, and autoimmune conditions. Founded in 2008 and headquartered in Abingdon, United Kingdom, Immunocore has established itself as a leader in the field of T-cell receptor (TCR) therapeutics. The company was co-founded by Dr. Bent Jakobsen, a renowned scientist in the field of immunology, and has since grown under the leadership of key executives, including CEO Bahija Jallal, who joined the company in 2019. Immunocore’s mission is to harness the power of the immune system to combat life-threatening diseases, leveraging its proprietary ImmTAC (Immune Mobilizing Monoclonal TCRs Against Cancer) technology platform.

Core Business Segments

Immunocore operates primarily in the biotechnology and pharmaceutical sectors, focusing on the development of TCR-based therapies. The company’s core business segments include:

1. Oncology

Immunocore’s flagship product, KIMMTRAK (tebentafusp-tebn), is the first and only FDA-approved TCR therapeutic for the treatment of metastatic uveal melanoma, a rare and aggressive form of eye cancer. KIMMTRAK represents a breakthrough in cancer immunotherapy, offering a novel mechanism of action that redirects T-cells to target and destroy cancer cells. The oncology segment remains a key focus for Immunocore, with additional pipeline candidates targeting other solid tumors and hematologic malignancies.

2. Infectious Diseases

Immunocore is actively developing TCR-based therapies for infectious diseases, including chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV). These programs aim to address significant unmet medical needs by leveraging the company’s expertise in immune modulation to develop curative treatments.

3. Autoimmune Diseases

The company is also exploring the application of its TCR technology to autoimmune diseases, with the goal of developing therapies that can selectively modulate the immune system to restore balance and prevent tissue damage.

Business Model

Immunocore’s business model is centered around its proprietary ImmTAC technology platform, which enables the development of highly specific and potent TCR-based therapies. The company generates revenue through a combination of product sales, licensing agreements, and strategic collaborations with pharmaceutical partners. Key elements of the business model include:

  • Product Sales: Revenue from the commercialization of KIMMTRAK and future pipeline products.
  • Collaborations and Partnerships: Immunocore has established partnerships with leading pharmaceutical companies, including Genentech and AstraZeneca, to co-develop and commercialize TCR-based therapies.
  • Research and Development (R&D): A significant portion of the company’s resources is dedicated to advancing its pipeline of innovative therapies, ensuring a steady flow of new products to the market.

Strategic Direction

Immunocore’s strategic priorities include:

  • Pipeline Expansion: The company is focused on advancing its clinical pipeline, with multiple candidates in various stages of development for oncology, infectious diseases, and autoimmune conditions.
  • Global Market Penetration: Immunocore aims to expand the availability of KIMMTRAK and future products to patients worldwide, leveraging its commercial infrastructure and partnerships.
  • Sustainability Goals: The company is committed to environmental sustainability and ethical business practices, integrating these principles into its operations and decision-making processes.
  • Innovation: Immunocore continues to invest in cutting-edge research to enhance its ImmTAC platform and explore new therapeutic modalities.

Competitive Landscape

Immunocore operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Adaptimmune Therapeutics: A leader in TCR-based therapies, focusing on oncology.
  • Amgen: A global biopharmaceutical company with a strong presence in oncology and immunotherapy.
  • Novartis: A multinational pharmaceutical company with a diverse portfolio of cancer therapies.
  • Gilead Sciences: Known for its expertise in infectious diseases and immunology.

Despite the competition, Immunocore differentiates itself through its proprietary ImmTAC platform and focus on rare and underserved diseases.

Risk Factors

Immunocore faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Risks: The development and approval of new therapies are subject to stringent regulatory requirements, which can be time-consuming and costly.
  • Market Dependence: The company’s revenue is heavily reliant on the success of KIMMTRAK, making it vulnerable to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: The global supply chain for pharmaceutical products is complex and susceptible to disruptions, which could affect the availability of raw materials and manufacturing capacity.
  • Clinical Trial Risks: The success of Immunocore’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain and may not yield favorable results.

Recent Developments

  • KIMMTRAK Commercialization: Immunocore has successfully launched KIMMTRAK in multiple markets, including the United States and Europe, achieving significant milestones in patient access and revenue generation.
  • Pipeline Progress: The company has reported positive clinical data for its HBV and HIV programs, demonstrating the potential of its TCR-based therapies in infectious diseases.
  • Strategic Partnerships: Immunocore has expanded its collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its pipeline candidates.
  • Global Developments: The COVID-19 pandemic has underscored the importance of innovative therapies, highlighting Immunocore’s role in addressing critical healthcare challenges.

Investment Considerations

Strengths

  • Innovative Technology: Immunocore’s ImmTAC platform represents a unique and highly differentiated approach to immunotherapy.
  • First-Mover Advantage: The approval of KIMMTRAK positions Immunocore as a leader in TCR-based therapies.
  • Strong Pipeline: A robust pipeline of candidates targeting high-value indications.
  • Strategic Partnerships: Collaborations with industry leaders enhance the company’s capabilities and market reach.

Risks

  • Revenue Concentration: Heavy reliance on KIMMTRAK for revenue generation.
  • Regulatory and Clinical Risks: Uncertainty surrounding the approval and success of pipeline products.
  • Competitive Pressure: Intense competition from established and emerging players in the biotechnology sector.

Conclusion

Immunocore Holdings PLC Sponsored ADR (IMCR) is a trailblazer in the field of TCR-based immunotherapies, with a strong focus on oncology, infectious diseases, and autoimmune conditions. The company’s innovative ImmTAC platform, combined with its commitment to addressing unmet medical needs, positions it as a leader in the biotechnology sector. While challenges remain, including regulatory and market risks, Immunocore’s robust pipeline, strategic partnerships, and global expansion efforts provide a solid foundation for future growth. Investors seeking exposure to cutting-edge biotechnology may find Immunocore an attractive opportunity, given its potential to deliver transformative therapies and generate long-term value.